Caricamento...
Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations
PURPOSE: The high expense of newer, more effective adjuvant endocrine therapy agents (aromatase inhibitors [AIs]) for postmenopausal breast cancer contributes to socioeconomic disparities in breast cancer outcomes. This study compares endocrine therapy costs for breast cancer patients during the fir...
Salvato in:
| Pubblicato in: | Springerplus |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer International Publishing
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4320689/ https://ncbi.nlm.nih.gov/pubmed/25674506 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40064-015-0827-8 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|